Spotlight On... First FDA-approved 3-D manufactured drug hits the market; India's Biological E expanding capacity; SP Industries buys PennTech Machinery; and more...

The first FDA-approved drug produced using a 3-D printing is now on the market. Aprecia Pharmaceuticals said this week that it has launched its epilepsy drug, Spritam that is manufactured through three-dimensional printing technology. Spritam is a formulation of levetiracetam that uses the process so the pills rapidly disintegrate with a sip of liquid, making them easier to swallow. Aprecia has two facilities for manufacturing, one in Blue Ash, OH, where the company is headquartered, and one in East Windsor, NJ. A spokesperson said the company is currently investing $25 million in its 190,000-square-foot Blue Ash manufacturing facility. Here's the release

> India's Biological E says it is investing more than $75 million (Rs 500 crore) on new manufacturing facilities in the next three years to increase both vaccine and generics manufacturing. Report

> France's Novasep is partnering with GTP Technology to provide mAb production services for European clients. Release

> Warminster, PA-based SP Industries has bought the assets of Warminster, PA-based PennTech Machinery, which makes pharma manufacturing equipment. Release

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)